3/5
12:51 pm
mrna
Is BioNTech SE (BNTX) A Good Stock To Buy Now? [Yahoo! Finance]
Low
Report
Is BioNTech SE (BNTX) A Good Stock To Buy Now? [Yahoo! Finance]
3/4
08:16 pm
mrna
Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears [Yahoo! Finance]
Medium
Report
Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears [Yahoo! Finance]
3/4
03:21 pm
mrna
The Sun Will Shine On Moderna Again - Initiating With A Buy [Seeking Alpha]
Low
Report
The Sun Will Shine On Moderna Again - Initiating With A Buy [Seeking Alpha]
3/4
11:17 am
mrna
Is Moderna Stock Outperforming the Dow? [Yahoo! Finance]
Medium
Report
Is Moderna Stock Outperforming the Dow? [Yahoo! Finance]
3/4
11:16 am
mrna
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom [Seeking Alpha]
Medium
Report
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom [Seeking Alpha]
3/4
10:32 am
mrna
Moderna to pay up to $2.25B to settle COVID vaccine patent matter [Yahoo! Finance]
Medium
Report
Moderna to pay up to $2.25B to settle COVID vaccine patent matter [Yahoo! Finance]
3/3
08:42 pm
mrna
Moderna Resolves Global Patent Litigation with Arbutus/Genevant [Yahoo! Finance]
Medium
Report
Moderna Resolves Global Patent Litigation with Arbutus/Genevant [Yahoo! Finance]
3/3
08:09 pm
mrna
Moderna (MRNA) was given a new $37.00 price target by Jefferies Financial Group Inc.. They now have a "hold" rating on the stock.
Medium
Report
Moderna (MRNA) was given a new $37.00 price target by Jefferies Financial Group Inc.. They now have a "hold" rating on the stock.
2/27
07:02 am
mrna
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 [Yahoo! Finance]
Medium
Report
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 [Yahoo! Finance]
2/23
07:17 am
mrna
Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
2/18
05:18 pm
mrna
Moderna says the FDA will consider its new flu shot after resolving a public dispute [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Moderna says the FDA will consider its new flu shot after resolving a public dispute [Globe and Mail, The (Toronto, Canada)]
2/18
04:24 pm
mrna
FDA backtracks and agrees to review Moderna mRNA flu vaccine after initial rejection [Fortune]
Medium
Report
FDA backtracks and agrees to review Moderna mRNA flu vaccine after initial rejection [Fortune]
2/18
12:25 pm
mrna
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal [MSNBC.com]
Low
Report
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal [MSNBC.com]
2/18
11:26 am
mrna
Moderna stock surges as FDA reverses course, agrees to review new flu shot [Yahoo! Finance Canada]
Low
Report
Moderna stock surges as FDA reverses course, agrees to review new flu shot [Yahoo! Finance Canada]
2/18
10:02 am
mrna
Moderna says the FDA will consider its new flu shot after resolving a public dispute [Yahoo! Finance Canada]
Low
Report
Moderna says the FDA will consider its new flu shot after resolving a public dispute [Yahoo! Finance Canada]
2/17
01:24 pm
mrna
Moderna (NASDAQ:MRNA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.
Medium
Report
Moderna (NASDAQ:MRNA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.
2/17
10:05 am
mrna
Moderna (NASDAQ:MRNA) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Moderna (NASDAQ:MRNA) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/17
10:04 am
mrna
Moderna (NASDAQ:MRNA) was given a new $35.00 price target on by analysts at Evercore Inc.
Low
Report
Moderna (NASDAQ:MRNA) was given a new $35.00 price target on by analysts at Evercore Inc.
2/17
08:02 am
mrna
Moderna (NASDAQ:MRNA) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
Medium
Report
Moderna (NASDAQ:MRNA) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
2/16
09:13 am
mrna
Moderna (NASDAQ:MRNA) was given a new $30.00 price target on by analysts at Morgan Stanley.
Medium
Report
Moderna (NASDAQ:MRNA) was given a new $30.00 price target on by analysts at Morgan Stanley.
2/16
08:11 am
mrna
Moderna (NASDAQ:MRNA) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Moderna (NASDAQ:MRNA) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
2/16
08:05 am
mrna
Moderna (NASDAQ:MRNA) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Moderna (NASDAQ:MRNA) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
2/13
04:46 pm
mrna
Moderna, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Moderna, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/13
02:15 pm
mrna
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial ... [Yahoo! Finance]
Low
Report
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial ... [Yahoo! Finance]
2/10
06:04 pm
mrna
Moderna says FDA refuses to review its application for experimental flu shot [CNBC]
Medium
Report
Moderna says FDA refuses to review its application for experimental flu shot [CNBC]